


Healthcare Industry News: HIV/AIDS
News Release - October 12, 2006
Ambrilia Biopharma and Merck & Co., Inc. Sign Licensing Agreement Granting Merck Worldwide Rights to Ambrilia's HIV/AIDS Protease Inhibitor Program
Source: Ambrilia Biopharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
